Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: Results from the COHIBA Study

L. Scalone, Lorenzo Giovanni Mantovani, F. Borghetti, S. von Mackensen, A. Gringeri, Giovanni Barillari, Elio Boeri, Alessandra Borchiellini, Teresa Caimi, Antonio Copola, Marco D'Incà, Pier Giorgio Iannaccaro, Alfonso Iorio, Massimo Morfini, Angiola Rocina

Research output: Contribution to journalArticle

Abstract

Despite modern highly efficacious technologies, there is still a lack of consensus on how to optimally treat haemophilia patients with inhibitors. The aim of the study was to evaluate preferences towards the characteristics of different coagulation factor concentrates for haemophilia inhibitors patients, from the perspective of patients or their caregivers, haematologists and pharmacists. A discrete choice study was conducted. Potential products were described with eight selected characteristics: perceived viral safety, risk of anamnestic response, possibility of undergoing major surgery, frequency of infusions in prophylaxis, number of infusions to stop bleeding, time to stop bleeding, time to pain recovery and cost. Participants received 16 pairs of potential products and chose from each pair the option they considered better. Data were analysed with a random-effects conditional logistic model. Totally 1614 observations were obtained from 37 patients/ caregivers, 39 physicians and 25 pharmacists from Italy. Cost was the most important characteristic to every group. For patients/caregivers, the next most important factors were: risk of anamnestic response, possibility of undergoing major surgery and perceived viral safety. For physicians, the next most important characteristics were: risk of anamnestic response, number of infusions to stop bleeding and possibility of undergoing major surgery. For pharmacists, the next most important factors were: time to stop bleeding, time to pain recovery and possibility of undergoing major surgery. Decisions on treatments must take into account patients' clinical needs; however, preferences can also play an important role in the choice and success of treatments. The results of this study could, therefore, help decision-makers to optimize the overall benefits of treatments.

Original languageEnglish
Pages (from-to)473-486
Number of pages14
JournalHaemophilia
Volume15
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Blood Coagulation Factors
Hemophilia A
Pharmacists
Physicians
Bleeding Time
Caregivers
Safety
Costs and Cost Analysis
Pain
Italy
Consensus
Therapeutics
Logistic Models
Hemorrhage
Technology

Keywords

  • Coagulation factor concentrates
  • Discrete choice experiment
  • Haemophilia
  • Inhibitors
  • Preferences
  • Willingness to pay

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors : Results from the COHIBA Study. / Scalone, L.; Mantovani, Lorenzo Giovanni; Borghetti, F.; von Mackensen, S.; Gringeri, A.; Barillari, Giovanni; Boeri, Elio; Borchiellini, Alessandra; Caimi, Teresa; Copola, Antonio; D'Incà, Marco; Iannaccaro, Pier Giorgio; Iorio, Alfonso; Morfini, Massimo; Rocina, Angiola.

In: Haemophilia, Vol. 15, No. 2, 2009, p. 473-486.

Research output: Contribution to journalArticle

Scalone, L, Mantovani, LG, Borghetti, F, von Mackensen, S, Gringeri, A, Barillari, G, Boeri, E, Borchiellini, A, Caimi, T, Copola, A, D'Incà, M, Iannaccaro, PG, Iorio, A, Morfini, M & Rocina, A 2009, 'Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: Results from the COHIBA Study', Haemophilia, vol. 15, no. 2, pp. 473-486. https://doi.org/10.1111/j.1365-2516.2008.01926.x
Scalone, L. ; Mantovani, Lorenzo Giovanni ; Borghetti, F. ; von Mackensen, S. ; Gringeri, A. ; Barillari, Giovanni ; Boeri, Elio ; Borchiellini, Alessandra ; Caimi, Teresa ; Copola, Antonio ; D'Incà, Marco ; Iannaccaro, Pier Giorgio ; Iorio, Alfonso ; Morfini, Massimo ; Rocina, Angiola. / Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors : Results from the COHIBA Study. In: Haemophilia. 2009 ; Vol. 15, No. 2. pp. 473-486.
@article{643dc180a8ae4267b1cc16e7e6fe7f47,
title = "Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: Results from the COHIBA Study",
abstract = "Despite modern highly efficacious technologies, there is still a lack of consensus on how to optimally treat haemophilia patients with inhibitors. The aim of the study was to evaluate preferences towards the characteristics of different coagulation factor concentrates for haemophilia inhibitors patients, from the perspective of patients or their caregivers, haematologists and pharmacists. A discrete choice study was conducted. Potential products were described with eight selected characteristics: perceived viral safety, risk of anamnestic response, possibility of undergoing major surgery, frequency of infusions in prophylaxis, number of infusions to stop bleeding, time to stop bleeding, time to pain recovery and cost. Participants received 16 pairs of potential products and chose from each pair the option they considered better. Data were analysed with a random-effects conditional logistic model. Totally 1614 observations were obtained from 37 patients/ caregivers, 39 physicians and 25 pharmacists from Italy. Cost was the most important characteristic to every group. For patients/caregivers, the next most important factors were: risk of anamnestic response, possibility of undergoing major surgery and perceived viral safety. For physicians, the next most important characteristics were: risk of anamnestic response, number of infusions to stop bleeding and possibility of undergoing major surgery. For pharmacists, the next most important factors were: time to stop bleeding, time to pain recovery and possibility of undergoing major surgery. Decisions on treatments must take into account patients' clinical needs; however, preferences can also play an important role in the choice and success of treatments. The results of this study could, therefore, help decision-makers to optimize the overall benefits of treatments.",
keywords = "Coagulation factor concentrates, Discrete choice experiment, Haemophilia, Inhibitors, Preferences, Willingness to pay",
author = "L. Scalone and Mantovani, {Lorenzo Giovanni} and F. Borghetti and {von Mackensen}, S. and A. Gringeri and Giovanni Barillari and Elio Boeri and Alessandra Borchiellini and Teresa Caimi and Antonio Copola and Marco D'Inc{\`a} and Iannaccaro, {Pier Giorgio} and Alfonso Iorio and Massimo Morfini and Angiola Rocina",
year = "2009",
doi = "10.1111/j.1365-2516.2008.01926.x",
language = "English",
volume = "15",
pages = "473--486",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors

T2 - Results from the COHIBA Study

AU - Scalone, L.

AU - Mantovani, Lorenzo Giovanni

AU - Borghetti, F.

AU - von Mackensen, S.

AU - Gringeri, A.

AU - Barillari, Giovanni

AU - Boeri, Elio

AU - Borchiellini, Alessandra

AU - Caimi, Teresa

AU - Copola, Antonio

AU - D'Incà, Marco

AU - Iannaccaro, Pier Giorgio

AU - Iorio, Alfonso

AU - Morfini, Massimo

AU - Rocina, Angiola

PY - 2009

Y1 - 2009

N2 - Despite modern highly efficacious technologies, there is still a lack of consensus on how to optimally treat haemophilia patients with inhibitors. The aim of the study was to evaluate preferences towards the characteristics of different coagulation factor concentrates for haemophilia inhibitors patients, from the perspective of patients or their caregivers, haematologists and pharmacists. A discrete choice study was conducted. Potential products were described with eight selected characteristics: perceived viral safety, risk of anamnestic response, possibility of undergoing major surgery, frequency of infusions in prophylaxis, number of infusions to stop bleeding, time to stop bleeding, time to pain recovery and cost. Participants received 16 pairs of potential products and chose from each pair the option they considered better. Data were analysed with a random-effects conditional logistic model. Totally 1614 observations were obtained from 37 patients/ caregivers, 39 physicians and 25 pharmacists from Italy. Cost was the most important characteristic to every group. For patients/caregivers, the next most important factors were: risk of anamnestic response, possibility of undergoing major surgery and perceived viral safety. For physicians, the next most important characteristics were: risk of anamnestic response, number of infusions to stop bleeding and possibility of undergoing major surgery. For pharmacists, the next most important factors were: time to stop bleeding, time to pain recovery and possibility of undergoing major surgery. Decisions on treatments must take into account patients' clinical needs; however, preferences can also play an important role in the choice and success of treatments. The results of this study could, therefore, help decision-makers to optimize the overall benefits of treatments.

AB - Despite modern highly efficacious technologies, there is still a lack of consensus on how to optimally treat haemophilia patients with inhibitors. The aim of the study was to evaluate preferences towards the characteristics of different coagulation factor concentrates for haemophilia inhibitors patients, from the perspective of patients or their caregivers, haematologists and pharmacists. A discrete choice study was conducted. Potential products were described with eight selected characteristics: perceived viral safety, risk of anamnestic response, possibility of undergoing major surgery, frequency of infusions in prophylaxis, number of infusions to stop bleeding, time to stop bleeding, time to pain recovery and cost. Participants received 16 pairs of potential products and chose from each pair the option they considered better. Data were analysed with a random-effects conditional logistic model. Totally 1614 observations were obtained from 37 patients/ caregivers, 39 physicians and 25 pharmacists from Italy. Cost was the most important characteristic to every group. For patients/caregivers, the next most important factors were: risk of anamnestic response, possibility of undergoing major surgery and perceived viral safety. For physicians, the next most important characteristics were: risk of anamnestic response, number of infusions to stop bleeding and possibility of undergoing major surgery. For pharmacists, the next most important factors were: time to stop bleeding, time to pain recovery and possibility of undergoing major surgery. Decisions on treatments must take into account patients' clinical needs; however, preferences can also play an important role in the choice and success of treatments. The results of this study could, therefore, help decision-makers to optimize the overall benefits of treatments.

KW - Coagulation factor concentrates

KW - Discrete choice experiment

KW - Haemophilia

KW - Inhibitors

KW - Preferences

KW - Willingness to pay

UR - http://www.scopus.com/inward/record.url?scp=63349090774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63349090774&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2008.01926.x

DO - 10.1111/j.1365-2516.2008.01926.x

M3 - Article

C2 - 19347988

AN - SCOPUS:63349090774

VL - 15

SP - 473

EP - 486

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 2

ER -